Jennifer Green, NP
Adult Health · Dalton, GANPI 1861623308
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.0% of the total across 246 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 15.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $1,470 and has fallen 51.8% since, to $709 in 2025.
Across 246 payments — averaging $18.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$695
- Dexcom, Inc.$409
- Medtronic$399
- Abbott$390
- Tandem Diabetes Care, Inc.$388
- Novo Nordisk$376
- plus $2K from 24 others
What the payments were for
- Food & beverage$4,55298%
- Education$321%
- Gifts$591%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 53 | $695 |
| Dexcom, Inc. | 18 | $409 |
| Medtronic | 14 | $399 |
| Abbott | 22 | $390 |
| Tandem Diabetes Care, Inc. | 19 | $388 |
| Novo Nordisk | 19 | $376 |
| Sanofi-aventis U.S. LLC | 16 | $374 |
| Insulet Corporation | 13 | $276 |
| Boehringer Ingelheim | 14 | $249 |
| Xeris Pharmaceuticals, Inc. | 9 | $186 |
| Mannkind Corporation | 8 | $177 |
| Amgen(2 entities) | 7 | $128 |
| Corcept Therapeutics | 5 | $108 |
| Zealand Pharma US, Inc. | 3 | $68 |
| AbbVie | 4 | $57 |
| Sequel Med Tech, LLC | 3 | $55 |
| AstraZeneca | 4 | $49 |
| Merck | 3 | $47 |
| BD | 1 | $30 |
| BETA Bionics, Inc. | 1 | $24 |
| Amryt Pharma Holdings Ltd | 1 | $22 |
| Inspire Medical Systems, Inc. | 1 | $20 |
| Novartis | 1 | $19 |
| Amneal Pharmaceuticals LLC | 1 | $16 |
| Esperion Therapeutics, Inc. | 1 | $16 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
| Ascendis Pharma Endocrinology Inc | 1 | $14 |
| EUSA Pharma (US) LLC | 1 | $12 |
| Recordati_rare_diseases_inc. | 1 | $12 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $12 |
How this compares
$4,643 in reported general payments places this provider in the 85th percentile of 577 adult health providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 516 | $599,078 |
| Tresiba Flextouch U-200Insulin Degludec | 397 | $360,267 |
| OzempicSemaglutide | 287 | $346,829 |
| JardianceEmpagliflozin | 284 | $255,993 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 187 | $210,193 |
| TrulicityDulaglutide | 155 | $182,923 |
| FarxigaDapagliflozin Propanediol | 187 | $160,221 |
| Humulin R U-500Insulin Regular, Human | 72 | $149,897 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 62 | $108,249 |
| Xultophy 100-3.6Insulin Degludec/Liraglutide | 69 | $98,393 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 69 | $81,638 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 110 | $68,615 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 53 | $67,300 |
| Omnipod Dash Pods (Gen 4)Insulin Pump Cart,cont Inf,bt | 38 | $62,296 |
| Tresiba Flextouch U-100Insulin Degludec | 131 | $61,878 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Lyumjev, Humalog, Insulin Lispro | $695 | $823,684781 claims |
| Novo NordiskOzempic, Xultophy 100-3.6, Novolog, Fiasp | $376 | $494,173483 claims |
| Boehringer IngelheimJardiance, Tradjenta | $249 | $280,580327 claims |
| AstraZenecaFarxiga | $49 | $160,221187 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $374 | $67,30053 claims |
| MerckJanuvia | $47 | $9,73013 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 577 adult health providers in Georgia.
Other adult health in Dalton
- Patricia KeeganAtlanta$224K
- Diane WirthAtlanta$132K
- Barbara WeberAtlanta$74K
- Terry HackworthAtlanta$49K
- Jenny DicksonCumming$39K
- Rachel NejemLawrenceville$31K
- Melissa BaughcumAthens$23K
- Kristine AdamsMarietta$21K
- Jenina LagascaAtlanta$17K
- Jennifer SheldonMacon$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.